| Literature DB >> 22925526 |
Ingmar Ipach1, Ralf Schäfer, Falk Mittag, Carmen Leichtle, Petra Wolf, Torsten Kluba.
Abstract
BACKGROUND: Most modern spinal implants contain titanium and remain in the patient's body permanently. Local and systemic effects such as tissue necrosis, osteolysis and malignant cell transformation caused by implants have been described. Increasing tissue concentration and whole blood levels of ions are necessary before a disease caused by a contaminant develops. The aim of the present study was the measurement of whole blood titanium levels and the evaluation of a possible correlation between these changes and the number of fused segments.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22925526 PMCID: PMC3495207 DOI: 10.1186/1471-2474-13-159
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Demographic data group I
| 1 | f | 73 | DLS | 10 | 1626 | 3 | MPDS | 56 | 34 | 26 | 29 | 37 |
| 2 | f | 55 | LS | 1 | 381 | 1 | MPDS | 33 | 44 | ø | 63 | 36 |
| 3 | f | 16 | Scoliosis | 6 | 864 | 0 | MADS | 34 | ø | 48 | ø | 31 |
| 4 | f | 16 | Scoliosis | 6 | 869 | 0 | MADS | 39 | 43 | 39 | ø | 96 |
| 5 | f | 22 | Scoliosis | 5 | 811 | 0 | MADS | 48 | ø | 42 | 54 | 94 |
| 6 | m | 45 | Scoliosis | 5 | 1076 | 2 | MADS | 54 | 42 | 44 | 55 | 31 |
| 7 | f | 68 | LS | 1 | 370 | 1 | Expedium | 53 | ø | 39 | 54 | 33 |
| 8 | f | 85 | LSCS | 4 | 824 | 1 | Expedium | 61 | 49 | 49 | 63 | 96 |
| 9 | f | 61 | LS | 1 | 410 | 1 | Expedium | 53 | ø | 49 | 40 | 47 |
| 10 | f | 61 | LSCS | 2 | 550 | 1 | Expedium | 49 | ø | 31 | 45 | 35 |
| 11 | m | 30 | LS | 1 | 405 | 1 | Expedium | 47 | 52 | ø | 40 | 142 |
| 12 | f | 42 | Scoliosis | 6 | 965 | 0 | MADS | 38 | ø | ø | 37 | 42 |
| 13 | f | 20 | Scoliosis | 11 | 1520 | 0 | Expedium | 51 | 42 | 3 | 38 | 37 |
| 14 | f | 55 | DLS | 6 | 1415 | 0 | Expedium | 69 | 33 | 37 | 32 | 36 |
| 15 | m | 58 | DLS | 4 | 540 | 0 | Expedium | 34 | 34 | 45 | 82 | 34 |
DLS: Degenerativ lumbar scoliosis, LS: lumbar spondylolisthesis, LSCS: lumbar spinal canal stenosis, MAPS: Muenster-Anterior-doublerod-system, MPDS: Muenster-posterior-doublerod-system.
Demographic data group II
| 1 | f | 26 | 59 |
| 2 | m | 55 | 47 |
| 3 | m | 33 | 30 |
| 4 | f | 24 | 37 |
| 5 | f | 55 | 33 |
| 6 | m | 24 | 35 |
| 7 | m | 31 | 57 |
| 8 | f | 50 | 59 |
| 9 | f | 28 | 58 |
| 10 | f | 29 | 55 |
| 11 | f | 50 | 56 |
| 12 | m | 29 | 61 |
| 13 | f | 24 | 33 |
| 14 | f | 24 | 53 |
| 15 | f | 20 | 58 |
| 16 | m | 30 | 59 |
Figure 1 Technique of length-measurement of the spinal fusion on lateral radiographs of the spine. The length of each screw and rod were added to obtain the total length of spinal fusion.
Figure 2 Technique for counting the different connections on a.p. radiographs of the spine.
Whole blood titanium levels in group I before and in the postoperative period
| before surgery | 47.9 | 15 | 10.6 | 33.0 | 69.0 |
| 2 th day after surgery | 41.4 | 9 | 6.7 | 33.0 | 52.0 |
| 10th day after surgery | 41.5 | 12 | 7.5 | 26.0 | 49.0 |
| 3 months after surgery | 48.6 | 13 | 15.0 | 29.0 | 82.0 |
| 12 months after surgery | 55.1 | 15 | 34.4 | 31.0 | 142.0 |
Figure 3 Development of titanium levels after spinal fusion in group I.
Figure 4 Individual development of titanium levels in the different patients.